Clinical Trials

70 enrolled

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT03971409 2026-04-17

InCITe

145 enrolled

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07328490 2026-04-17

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

120 enrolled

Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT07011654 2026-04-16

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Phase 1/2 Recruiting

31 enrolled

Triple Negative Breast Neoplasms

NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Phase 3 Recruiting

364 enrolled

Triple Negative Breast Neoplasms

NCT06524544 2026-04-15

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

320 enrolled

Carcinoma, Transitional Cell

NCT06161532 2026-04-14

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

60 enrolled

Phase 3 Active not recruiting

Carcinoma, Transitional Cell

NCT04579224 2026-04-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

184 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06311214 2026-04-13

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Phase 2 Not yet recruiting

500 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07504588 2026-04-13

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

87 enrolled

Gynecologic

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT04794699 2026-04-09

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Phase 1 Active not recruiting

169 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

NCT07339059 2026-04-09

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

35 enrolled

Phase 3 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05382299 2026-04-06

ASCENT-03

623 enrolled

Triple Negative Breast Neoplasms

NCT04559230 2026-03-30

Sacituzumab Govitecan in Recurrent Glioblastoma

Other solid neoplasmThoracic

32 enrolled

CNS

Glioblastoma

NCT04826341 2026-03-27

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Phase 1/2 Recruiting

120 enrolled

HRD Cancer

NCT05226117 2026-03-27

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Phase 2 Completed

44 enrolled

Carcinoma, Transitional Cell

NCT05601440 2026-03-27

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

484 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07438600 2026-03-27

TianjinCIH

38 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07492914 2026-03-25

Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

30 enrolled

Head & Neck

Head and Neck Neoplasms

NCT05884320 2026-03-20

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

30 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT06801834 2026-03-19

EVOKE-SCLC-04

Phase 3 Recruiting

695 enrolled